var data={"title":"Pyrimethamine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pyrimethamine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6880?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">see &quot;Pyrimethamine: Drug information&quot;</a> and <a href=\"topic.htm?path=pyrimethamine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pyrimethamine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216093\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Daraprim</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216094\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Daraprim [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049610\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antimalarial Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11444903\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Congenital toxoplasmosis (independent of HIV status); treatment:</b> Oral: Initial: 2 mg/kg/day once daily for 2 days, then 1 mg/kg/day once daily given with sulfadiazine for 2 to 6 months; then 1 mg/kg/day 3 times/week (eg, MWF) with sulfadiazine; total treatment duration: 12 months; oral leucovorin should be administered throughout the entire course to prevent hematologic toxicity (DHHS [pediatric], 2013; McAuley, 2008) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049604\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">see &quot;Pyrimethamine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Isosporiasis <i>(Isospora belli)</i>, HIV-exposed/-positive:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <span style=\"text-decoration: underline\">Treatment: </span></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children: Oral: 1 mg/kg once daily in combination with leucovorin for 14 days; maximum daily dose: 75 mg/<b>day </b>(DHHS [pediatric], 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents: Oral: 50 to 75 mg once daily in combination with leucovorin (DHHS [adult], 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <span style=\"text-decoration: underline\">Chronic maintenance: </span></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children: Oral: 1 mg/kg once daily in combination with leucovorin; maximum daily dose: 25 mg/<b>day</b> (DHHS [pediatric], 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents: Oral: 25 mg once daily in combination with leucovorin (DHHS [adult], 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Toxoplasmosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <span style=\"text-decoration: underline\">Treatment: </span></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Congenital toxoplasmosis (independent of HIV status): Oral: Infants: Initial: 2 mg/kg/dose once daily for 2 days, then 1 mg/kg/day once daily given with sulfadiazine for 2 to 6 months; then 1 mg/kg/day 3 times/week (eg, MWF) with sulfadiazine; oral leucovorin should be administered throughout entire course to prevent hematologic toxicity (total treatment duration: 12 months) (DHHS [pediatric], 2013; McAuley, 2008) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acquired infection: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>HIV-exposed/-positive:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Infants and Children: Oral: 2 mg/kg (maximum dose: 50 mg/dose) once daily for 3 days followed by 1 mg/kg (maximum dose: 25 mg) once daily in combination with sulfadiazine or clindamycin and leucovorin; continue for at least 6 weeks; consider longer duration if clinical or radiologic disease is extensive or incomplete response; follow with chronic suppressive therapy (DHHS [pediatric], 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Adolescents: Oral: Encephalitis: 200 mg once as a single dose, followed by weight-based daily dosing: For weight &lt;60 kg: 50 mg or for weight &ge;60 kg: 75 mg once daily, typically used in combination with sulfadiazine and leucovorin; other combination regimens include clindamycin, atovaquone, or azithromycin and leucovorin; continue for at least 6 weeks; consider longer duration if clinical or radiologic disease is extensive or incomplete response (DHHS [adult], 2013) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Non-HIV-exposed/-positive</i> (<i>Red Book</i> [AAP, 2012]): <b>Note:</b> Use in combination with sulfadiazine or clindamycin; oral leucovorin should be administered to prevent hematologic toxicity. Continue therapy until 1 to 2 weeks after the resolution of symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children: Oral: 2 mg/kg (maximum dose: 50 mg/dose) once daily for 2 days, followed by 1 mg/kg/day (maximum dose: 25 mg/dose) once daily for 3 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Adolescents: Oral: 200 mg once as a single dose; then 50 to 75 mg once daily for 3 to 6 weeks  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <span style=\"text-decoration: underline\">Prophylaxis:</span></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">First episode of <i>Toxoplasma gondii:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>HIV-exposed/-positive:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Infants and Children (DHHS [pediatric], 2013): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">In combination with dapsone: 1 mg/kg/day once daily (maximum dose: 25 mg/dose) with dapsone plus oral leucovorin </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">In combination with atovaquone: Infants and Children 4 to 24 months: 1 mg/kg or 15 mg/m<sup>2</sup> once daily (maximum dose: 25 mg/dose) with atovaquone plus oral leucovorin </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Adolescents (DHHS [adult], 2013): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">In combination with dapsone: 50 mg or 75 mg once <b>weekly</b> plus oral leucovorin </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">In combination with atovaquone: 25 mg once <b>daily</b> plus leucovorin </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Hematopoietic cell transplantation recipients</i> (Tomblyn, 2009): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Infants and Children: Oral: 1 mg/kg/day of pyrimethamine once daily (maximum single dose: 75 mg) with clindamycin and leucovorin. Start after engraftment and administer as long as the patient remains on immunosuppressive therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Adolescents: Oral: 25 to 75 mg once daily with clindamycin and leucovorin. Start after engraftment and administer as long as the patient remains on immunosuppressive therapy. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Recurrence of <i>Toxoplasma gondii</i> (secondary prophylaxis; suppressive therapy): HIV-exposed/-positive: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants and Children: Oral: 1 mg/kg or 15 mg/m<sup>2</sup> once daily (maximum dose: 25 mg) with sulfadiazine, clindamycin, or atovaquone, plus oral leucovorin (DHHS [pediatric], 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adolescents (DHHS [adult], 2013): Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">In combinations with sulfadiazine or clindamycin: 25 to 50 mg once daily plus leucovorin </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">In combination with atovaquone: 25 mg once daily plus leucovorin </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Malaria:</b> <b>Note:</b> Current CDC recommendations for malaria prophylaxis or treatment do not include the use of pyrimethamine; resistance to pyrimethamine is prevalent worldwide. (CDC, 2013); however, pyrimethamine is still discussed in the World Health Organization (WHO) treatment guidelines (WHO, 2010; WHO, 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <span style=\"text-decoration: underline\">Chemoprophylaxis:</span> Begin prophylaxis before entering endemic area:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children &lt;4 years: Oral: 6.25 mg once weekly </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 4 to 10 years: Oral: 12.5 mg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &gt;10 years and Adolescents: Oral: 25 mg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <span style=\"text-decoration: underline\">Treatment (non-<i>falciparum</i> malaria; use in conjunction with a sulfonamide [eg, sulfadoxine]):</span></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 4 to 10 years: Oral: 25 mg daily for 2 days; following clinical cure, administer a once-weekly chemoprophylaxis regimen for &ge;10 weeks. <b>Note:</b> Pyrimethamine monotherapy is generally not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &gt;10 years and Adolescents: Oral: 25 mg daily for 2 days; following clinical cure, administer a once-weekly chemoprophylaxis regimen for &ge;10 weeks. <b>Note:</b> Pyrimethamine monotherapy is <b>not</b> recommended; if circumstances arise where it must be used alone in semi-immune patients, give 50 mg daily for 2 days; then (following clinical cure) administer a once-weekly chemoprophylaxis regimen for &ge;10 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>\n        <i>Pneumocystis jirovecii</i> pneumonia (PCP) (HIV-exposed/-positive); primary prophylaxis or chronic maintenance (secondary prophylaxis) </b> (DHHS [adult], 2013): Adolescents: Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">In combination with dapsone and leucovorin: 50 to 75 mg once <b>weekly</b> with dapsone and leucovorin </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">In combination with atovaquone and leucovorin: 25 mg once <b>daily</b>with atovaquone and leucovorin </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Isosporiasis (<i>Isospora belli</i> infection) in HIV-positive/-exposed patients</b> (DHHS [adult], 2013): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Treatment: 50 to 75 mg once daily in combination with leucovorin </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chronic maintenance (secondary prophylaxis): 25 mg once daily in combination with leucovorin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Malaria chemoprophylaxis:</b> Oral: <b>Note:</b> Current CDC recommendations for malaria prophylaxis do not include the use of pyrimethamine; resistance to pyrimethamine is prevalent worldwide.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Manufacturer's labeling: 25 mg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Malaria treatment (non-<i>falciparum</i> malaria; use in conjunction with a sulfonamide [eg, sulfadoxine]):</b> Oral: <b>Note:</b> Current CDC recommendations for malaria treatment do not include the use of pyrimethamine; resistance to pyrimethamine is prevalent worldwide.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Manufacturer's labeling: 25 mg daily for 2 days; following clinical cure, administer a once-weekly chemoprophylaxis regimen for &ge;10 weeks. <b>Note:</b> Pyrimethamine use alone is <b>not</b> recommended; if circumstances arise where it must be used alone in semi-immune patients, give 50 mg daily for 2 days; then (following clinical cure) administer a once-weekly chemoprophylaxis regimen for &ge;10 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Toxoplasmosis in HIV-positive/-exposed patients:</b> (DHHS [adult], 2013): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prophylaxis for first episode of <i>Toxoplasma gondii</i>: 50 mg or 75 mg once weekly with dapsone, plus oral leucovorin <b>or</b> 25 mg once daily with atovaquone plus leucovorin </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prophylaxis to prevent recurrence of <i>Toxoplasma gondii</i>: 25 to 50 mg once daily in combination with sulfadiazine plus oral leucovorin <b>or</b> 25 to 50 mg once daily with clindamycin in combination with oral leucovorin <b>or</b> 25 mg once daily with atovaquone in combination with leucovorin </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Treatment of <i>Toxoplasma gondii</i> encephalitis: 200 mg as a single dose, followed by 50 mg (&lt;60 kg patients) or 75 mg (&ge;60 kg patients) daily, plus sulfadiazine and leucovorin <b>or</b> 200 mg as a single dose, followed by 50 mg (&lt;60 kg patients) or 75 mg (&ge;60 kg patients) daily, with clindamycin, atovaquone, or azithromycin in combination with oral leucovorin; continue treatment for at least 6 weeks; longer if clinical or radiologic disease is extensive or response is incomplete at 6 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216067\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Daraprim: 25 mg [scored]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216052\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45511770\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">As of June 2015, pyrimethamine is no longer available in retail pharmacies in the United States. It is available through a special pharmacy program (http://www.daraprimdirect.com/healthcare-providers).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alternate availability information for a compounded formulation may be found at http://www.hivma.org/Pyrimethamine_Alternatives/.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049613\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with meals to minimize vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216089\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F). Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049612\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Used in combination with sulfadiazine for treatment of toxoplasmosis [FDA approved in pediatric patients (age not specified) and adults]; chemoprophylaxis and treatment of malaria [FDA approved in pediatric patients (age not specified) and adults]; has also been used in combination with dapsone as primary or secondary prophylaxis for <i>Pneumocystis jirovecii</i> in HIV-infected patients. <b>Note:</b> Although an FDA labeled indication, the use of pyrimethamine for chemoprophylaxis or treatment of malaria is not routinely recommended due to severe adverse reactions and reports of resistance (CDC, 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216134\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Daraprim may be confused with Dantrium, Daranide</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216132\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac arrhythmia (large doses)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema multiforme, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, glossitis (atrophic), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Leukopenia, megaloblastic anemia, pancytopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Hematuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Eosinophilic pneumonitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216074\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to pyrimethamine or any component of the formulation; megaloblastic anemia secondary to folate deficiency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216056\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hematologic: Megaloblastic anemia, leukopenia, thrombocytopenia, and pancytopenia have been reported; most commonly with high doses. Monitor CBC and platelets twice weekly in patients receiving high-dose therapy (eg, when used for toxoplasmosis treatment).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Folate deficiency: Use caution in patients with possible folate deficiency (eg, malabsorption syndrome, pregnancy, alcoholism).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; G6PD deficiency: Use with caution in patients with possible G6PD deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull;\t Leucovorin: Administer leucovorin to prevent hematologic complications due to pyrimethamine-induced folic acid deficiency state; continue leucovorin during therapy and for 1 week after therapy is discontinued (to account for long half-life of pyrimethamine) (HHS [OI pediatric, 2013)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216123\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2C9 (moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216061\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12754&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Bosentan.  Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended.  See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Substrates (High risk with Inhibitors): CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lornoxicam: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Lornoxicam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Pyrimethamine may enhance the adverse/toxic effect of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylfolate: May diminish the therapeutic effect of Pyrimethamine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PEMEtrexed: Pyrimethamine may enhance the adverse/toxic effect of PEMEtrexed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PRALAtrexate: Pyrimethamine may enhance the adverse/toxic effect of PRALAtrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proguanil: Pyrimethamine may enhance the adverse/toxic effect of Proguanil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltitrexed: Pyrimethamine may enhance the adverse/toxic effect of Raltitrexed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonamide Antibiotics: Pyrimethamine may enhance the adverse/toxic effect of Sulfonamide Antibiotics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: Pyrimethamine may enhance the adverse/toxic effect of Trimethoprim. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216063\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216078\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. If administered during pregnancy (ie, for toxoplasmosis), supplementation of folate is strongly recommended. Pregnancy should be avoided during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049609\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC, including platelet counts twice weekly with high-dose therapy (eg, when used for toxoplasmosis treatment; frequency not defined for lower doses); liver and renal function </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216055\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits parasitic dihydrofolate reductase, resulting in inhibition of vital tetrahydrofolic acid synthesis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216073\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Adults: 2.9 L/kg; distributed to the kidneys, lung, liver, and spleen</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 87% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 80 to 95 hours (White 1985)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 2 to 6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (16% to 32%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216072\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 2 mg/mL oral suspension may be made with tablets and a 1:1 mixture of Simple Syrup, NF and methylcellulose 1%. Crush forty 25 mg tablets in a mortar and reduce to a fine powder. Add small portions of vehicle and mix to a uniform paste; mix while adding vehicle in incremental proportions to <b>almost</b> 500 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 500 mL. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Stable for 91 days.</p>\n    <div class=\"reference\">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216077\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Daraprim Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $27,000.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216080\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Daraprim (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CL, CY, CZ, DE, EG, ES, ET, GB, GH, GM, GN, GR, GY, HK, IE, IL, IN, IQ, IR, JM, JO, KE, KR, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, NE, NG, NL, NO, OM, PE, PL, QA, SA, SC, SD, SI, SL, SN, SR, SY, TN, TT, TW, TZ, UG, UY, YE, ZA, ZM, ZW);</li>\n      <li>Daraprin (BR);</li>\n      <li>Malocide (FR);</li>\n      <li>Malomin (BD);</li>\n      <li>Meta (LK);</li>\n      <li>Primet (ID);</li>\n      <li>Pyrison (BD);</li>\n      <li>Tindurin (BD, HU);</li>\n      <li>Toxopirin (CR, DO, GT, HN, NI, PA, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Guidelines for treatment of malaria in the United States, treatment table update, 2013a. Available at <a href=\"http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf\" target=\"_blank\">http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daraprim tablet (pyrimethamine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2003.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections (OI) in HIV-Infected Adults and Adolescents. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA),&quot; May 7, 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 6, 2013. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McAuley JB, &quot;Toxoplasmosis in Children,&quot;<i> Pediatr Infect Dis J</i>, 2008, 27(2):161-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrimethamine-pediatric-drug-information/abstract-text/18227714/pubmed\" target=\"_blank\" id=\"18227714\">18227714</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>, &quot;Antibacterial Drugs Dosage Tables,&quot; 29th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2012, 808-16. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomblyn M, Chiller T, Einsele H, et al, &quot;Guidelines for Preventing Infectious Complications Among Hematopoietic Cell Transplantation Recipients: A Global Perspective,&quot; <i>Biol Blood Marrow Transplant</i>, 2009, 15(10):1143-238. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrimethamine-pediatric-drug-information/abstract-text/19747629/pubmed\" target=\"_blank\" id=\"19747629\">19747629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization, &ldquo;Guidelines for the Treatment of Malaria,&rdquo; 2010, World Health Organization, Geneva. Available at http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization, &ldquo;Guidelines for the Treatment of Malaria,update 2010,&quot; World Health Organization, Geneva. Available at http://www.who.int/malaria/publications/atoz/mal_treatchild_revised.pdf </div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12754 Version 106.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F216093\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F216094\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1049610\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11444903\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1049604\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F216067\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F216052\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F45511770\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1049613\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F216089\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1049612\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F216134\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F216132\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F216074\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F216056\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F216123\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F216061\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F216063\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F216078\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1049609\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F216055\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F216073\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F216072\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F216077\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F216080\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12754|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">Pyrimethamine: Drug information</a></li><li><a href=\"topic.htm?path=pyrimethamine-patient-drug-information\" class=\"drug drug_patient\">Pyrimethamine: Patient drug information</a></li></ul></div></div>","javascript":null}